Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Basal vein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Basal vein. Displaying page 1 of 1.
    EudraCT Number: 2016-003093-40 Sponsor Protocol Number: FADOI_032016 Start Date*: 2017-03-10
    Sponsor Name:FONDAZIONE FADOI
    Full Title: Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end point (PROBE) study- the CARAVAGGIO study.
    Medical condition: Venous thromboembolism in cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) PT (Completed) PL (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003342-25 Sponsor Protocol Number: P170604J Start Date*: 2018-09-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Long-term treatment of cancer associated VTE Optimal dose of apixaban API-CAT STUDY for APIxaban Cancer Associated Thrombosis
    Medical condition: Patients with breast, prostate, and colorectal active cancer, with objectively documented index event of symptomatic or incidental proximal DVT or symptomatic or incidental PE, after 6 months of an...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10076654 Cancer-associated thrombosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) PL (Ongoing) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Completed) GR (Completed) AT (Ongoing) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006439-12 Sponsor Protocol Number: INSIGHT001:STARTDAIDSID#10619 Start Date*: 2009-05-25
    Sponsor Name:Regents of the University of Minnesota
    Full Title: Strategic Timing of AntiRetroviral Treatment(START)
    Medical condition: HIV Infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) GR (Completed) IT (Completed) SE (Completed) PT (Completed) IE (Completed) EE (Completed) NO (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-004708-30 Sponsor Protocol Number: DU176b-D-U311 Start Date*: 2015-05-07
    Sponsor Name:Daiichi Sankyo , Inc.
    Full Title: A PHASE 3B, PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF (LMW) HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED W...
    Medical condition: venous thromboembolism associated with cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BE (Completed) IT (Completed) DE (Completed) ES (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002210-41 Sponsor Protocol Number: 29BRC20.0021 Start Date*: 2020-06-29
    Sponsor Name:CHRU de Brest
    Full Title: Screening for occult malignancy using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in patients with unprovoked venous thromboembolism
    Medical condition: Embolism venous Neoplasm malignant
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    21.1 10047065 - Vascular disorders 10014522 Embolism venous PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003076-14 Sponsor Protocol Number: ANT-007 Start Date*: 2022-05-10
    Sponsor Name:Anthos Therapeutics
    Full Title: A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in ...
    Medical condition: venous thromboembolism (VTE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003954-42 Sponsor Protocol Number: FPS-INSUPAR-2015-01 Start Date*: 2016-01-27
    Sponsor Name:Fundación Pública Andaluza Progreso y Salud
    Full Title: Subcutaneous versus intravenous basal insulin in non-critical hospitalized diabetic patients receiving total parenteral nutrition
    Medical condition: Diabetes mellitus (DM) is a group of metabolic disorders that causes high levels of blood glucose (hyperglycemia) which are persistent or chronic. DM presents epidemic proportions in most of the wo...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-005236-32 Sponsor Protocol Number: FRAG-A001-401 Start Date*: 2009-09-23
    Sponsor Name:Eisai Inc
    Full Title: Dalteparin Sodium Injection (Fragmin®), Multicenter, Open Label, Single-arm, Long Term (52 weeks) Study for Understanding Safety and Efficacy in Subjects with Malignancies and Symptomatic Venous Th...
    Medical condition: Venous thromboembolism in patients with malignancies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000392-37 Sponsor Protocol Number: Protocol_version_1_09-02-2021 Start Date*: 2021-11-02
    Sponsor Name:Oslo University Hospital
    Full Title: A double-blind randomized placebo-controlled four-arm trial to assess the efficacy of oral bicarbonate and intravenous butylscopolamine bromide to facilitate spontaneous (non-operative) delivery in...
    Medical condition: Nulliparous women with induction of labor at term and a singleton fetus in vertex position
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004857-86 Sponsor Protocol Number: CTP_CAP001 Start Date*: 2007-01-19
    Sponsor Name:Caprion Pharmaceuticals Inc.
    Full Title: A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidne...
    Medical condition: metastatic kidney cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10023405 Kidney cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000252-28 Sponsor Protocol Number: SHCVOLT1 Start Date*: 2009-03-13
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A Multi-Centre Prospective Controlled Trial Comparing Calcineurin Inhibitor Monotherapy With Sirolimus Monotherapy in Hepatitis C Infected Patients with Hepatic Fibrosis Following Liver Transplanta...
    Medical condition: Patients who have undergone liver transplantation and are infected with Hepatitis C virus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052779 Transplant rejections HLT
    9.1 10024970 Respiratory tract infections HLGT
    9.1 10046577 Urinary tract infections HLT
    9.1 10001032 Acute pyelonephritis LLT
    9.1 10040072 Septicaemia LLT
    9.1 10019972 Herpes viral infections HLT
    9.1 10028440 Mycobacterial infectious disorders HLGT
    9.1 10015107 Epstein-Barr viral infections HLT
    9.1 10011831 Cytomegalovirus infection LLT
    9.1 10019974 Herpes zoster LLT
    9.1 10058872 Fungal sepsis LLT
    9.1 10040808 Skin cancer PT
    9.1 10051358 Post transplant lymphoproliferative disorder LLT
    9.1 10043555 Thrombocytopenias HLT
    9.1 10037561 Purpura thrombocytopenic LLT
    9.1 10002034 Anaemia PT
    9.1 10018932 Haemolytic uraemic syndrome PT
    9.1 10024384 Leukopenia PT
    9.1 10029355 Neutropenias HLT
    9.1 10033661 Pancytopenia PT
    9.1 10013505 Disturbance of liver function tests LLT
    9.1 10002218 Anaphylaxis LLT
    9.1 10002425 Angioedemas HLT
    9.1 10015665 Exfoliative dermatitis LLT
    9.1 10020764 Hypersensitivity vasculitis LLT
    9.1 10021015 Hypokalaemia PT
    9.1 10021058 Hypophosphataemia PT
    9.1 10020603 Hypercholesterolaemia PT
    9.1 10020635 Hyperglycaemia PT
    9.1 10020869 Hypertriglyceridaemia PT
    9.1 10043071 Tachycardia PT
    9.1 10034474 Pericardial effusion PT
    9.1 10048642 Lymphocele PT
    9.1 10051055 Deep vein thrombosis PT
    9.1 10037377 Pulmonary embolism PT
    9.1 10025282 Lymphoedema PT
    9.1 10035742 Pneumonitis PT
    9.1 10035598 Pleural effusion PT
    9.1 10015090 Epistaxis PT
    9.1 10037394 Pulmonary haemorrhage PT
    9.1 10000081 Abdominal pain PT
    9.1 10012735 Diarrhoea PT
    9.1 10042128 Stomatitis PT
    9.1 10033645 Pancreatitis PT
    9.1 10000496 Acne PT
    9.1 10037844 Rash PT
    9.1 10003239 Arthralgia PT
    9.1 10031264 Osteonecrosis PT
    9.1 10037032 Proteinuria PT
    9.1 10029164 Nephrotic syndrome PT
    9.1 10030124 Oedema peripheral PT
    9.1 10021519 Impaired healing PT
    9.1 10030095 Oedema PT
    9.1 10037660 Pyrexia PT
    9.1 10005630 Blood lactate dehydrogenase increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023453-11 Sponsor Protocol Number: CXA-cUTI-10-05 Start Date*: 2011-08-04
    Sponsor Name:Cubist Pharmaceuticals, Inc.
    Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE SAFETY AND EFFICACY OF INTRAVENOUS CXA 201 AND INTRAVENOUS LEVOFLOXACIN IN COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELO...
    Medical condition: Complicated Urinary Tract Infection, Including Pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10046577 Urinary tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) ES (Prematurely Ended) SI (Completed) BG (Completed) EE (Prematurely Ended) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005405-37 Sponsor Protocol Number: NH19960 Start Date*: 2006-06-28
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapy
    Medical condition: Anemic patients undergoing chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) BE (Completed) ES (Completed) CZ (Completed) EE (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000758-20 Sponsor Protocol Number: DIV-SCLC-301 Start Date*: 2017-06-21
    Sponsor Name:United Therapeutics Corporation
    Full Title: A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer
    Medical condition: relapsed or refractory small cell lung cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) BG (Completed) LT (Completed) FR (Completed) PL (Completed) SK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:55:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA